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HER3 Receptor: 
• Tyrosine kinase receptor that is overexpressed in various 
cancers including breast, ovarian, prostate, and lung cancer
• Has a weak intracellular kinase domain and relies on forming 
heterodimers with other members of the HER family to 
promote downstream signaling
• Responsible for patient resistance to therapeutics that target 
other members of the HER family 
Clinical Need: 
• No HER3 targeting therapeutic has received FDA approval
• HER3 overexpression can result in poor prognosis for several 
cancers, including lung adenocarcinomas 
• Targeted therapy allows for site-directed therapy; reduces risk 
of affecting healthy tissue
Objectives: 
• Engineer and optimize bivalent HER3 affibodies for enhanced 
therapeutic potential 
• Modify bivalent HER3 affibody linker domain length and test 
affibody efficacy 
PURPOSE
Affibodies Used for Cell Assays: 
• Affibody with linker domain comprised of 1, 2, 3, or 4 repeating 
units (Figure 1)
• A minimal linker made with 3 glycine amino acids
Creating the Constructs: 
• Original bivalent HER3 affibody was made up of 3 repeats of the 
following sequence called L20: ASGAGGSEGGGSEGGTSGAT 
• Each repeat unit has a length of ~7nm 
• The 1 link, 2 link, 3 link, 4 link, and minimal linker bivalent HER3 
affibody constructs were created using mutagenesis 
• Vectors were transformed into and expressed in BL21 (DE3) 
competent E. coli cells 
• Competent cells were induced, lysed, and purified
Cell Signaling Assay: 
• Cells were serum starved for 3 hours treated with indicated 
concentrations of affibodies, stimulated with NRG, lysed, and 
prepped for immunoblotting
• Immunoblots were probed with indicated primary antibodies 
Downregulation Assay: 
• Cells were treated with indicated concentrations of affibodies 
for 3 or 24 hours, lysed, and prepped for immunoblotting
• Immunoblots were probed with indicated primary antibodies
METHODS
RESULTS CONCLUSIONS
• Linker domain design such as altering flexibility and length are 
important for developing optimized therapeutics; however, 
bivalent HER3 affibody efficacy is not affected by linker domain 
length
• Affibody constructs including the 1 link, 2 link, 3 link, 4 link, and 
minimal link (3 aa linker) were all effective at promoting 
inhibition of HER3 and Akt phosphorylation 
• The 1 link, 2 link, 3 link, and 4 link affibodies effectively 
inhibited HER3 phosphorylation in OvCAR8, Du145, H1975, and 
BT474 cell lines
• The bivalent HER3 affibody with the 3 aa linker also 
demonstrated comparable HER3 downregulation as seen with 
the original bivalent HER3 affibody (3 link) design
• Smaller proteins, such as the bivalent HER3 affibody with the 3 
aa linker, result in better tissue penetration
• Minimal linkers may also result in therapeutics with lower 
immunogenicity risks
• The reduction in immunogenicity risks allows for enhanced 
translational potential
Future Work: 
• Optimize affibodies using an albumin binding domain to 
increase affibody half-life for in vivo testing
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• Figure 1A: Abstract representation of affibody constructs 
• Figure 1B: Molecular weights of 1, 2, 3, and 4 linker bivalent HER3 
affibodies are 16.0, 17.5, 19.1, 20.6 kDa, respectively 
• Figure 1C: Immunoblots of cell signaling study comparing efficacy 
of 1, 2, 3, and 4 link Bivalent HER3 affibodies
• Bivalent HER3 affibodies inhibited pHER3/pAkt for all linker 
lengths tested in multiple cell lines
• 1 link bivalent HER3 affibody (~7nm) also maintained efficacy even 
though it theoretically is not long enough to cross the 10nm 
distance between homodimerized HER3 binding domains
Figure 2: Immunoblots comparing pHER3/pAkt 
inhibition and HER3 downregulation of the GGG 
minimal linker and the original 3 link bivalent 
affibody for the OvCAR8 cell line
Figure 1: Immunoblots comparing pHER3/pAkt 
inhibition of the 1, 2, 3, and 4 link bivalent 
affibodies
• Figure 2A: Abstract representation of affibody constructs
• Figure 2B: MW of 3 aa linker and 64 aa linker affibodies are 14.4 
and 19.1 kDa, respectively  
• Figure 2C: Immunoblots of cell signaling study comparing efficacy 
of the bivalent HER3 affibodies with the 3 aa and the 64 aa linker 
(3 link)
• Figure 2D: Immunoblots of HER3 downregulation study comparing 
efficacy of bivalent HER3 affibodies with the 3 aa and 64 aa linker
• pHER3/pAkt inhibition and HER3 downregulation was similar for 
both the original 3 link linker bivalent HER3 affibody (64 aa linker) 
and the minimal linker bivalent HER3 affibody (3 aa linker)
• 64 aa linker is ~20nm in length
• 3 aa linker is ~1nm in length 
